PD-1 Pandemonium at the American Association for Cancer Research Annual Meeting

[摘要] This editorial describes the results of discussions between the U.S. FDA Oncology Center of Excellence and members of six pharmaceutical companies—a forum aptly named PD-1 Pandemonium—regarding development and regulatory approvals of immune checkpoint inhibitors.

[学科分类] 地质学